Investors might want to bet on UNITY Biotechnology, Inc. (UBX), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate was ...
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...
SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today ...
Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies. Unity’s restructuring comes along with 36-week results from its phase 2b ...
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today ...
Hosted on MSN
Chardan Capital Initiates Coverage of Unity Biotechnology (UBX) with Buy Recommendation
Fintel reports that on January 10, 2025, Chardan Capital initiated coverage of Unity Biotechnology (NasdaqGS:UBX) with a Buy recommendation. Analyst Price Forecast Suggests 277.88% Upside As of ...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...
"I look forward to collaborating with the UNITY team to advance the lead senolytic program and shape an exciting pipeline of future products." Keith R. Leonard Jr., chairman of the board of UNITY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback